
|Videos|September 23, 2016
George P. Kim, MD: Importance of CA19-9 and Albumin Markers
Advertisement
Episodes in this series

What is the importance of markers such as CA19-9 and albumin for diagnosis and response prediction in pancreatic cancer?
Metastatic Pancreatic Cancer: Case 2
Henry R was diagnosed with adenocarcinoma in the body of the pancreas when he was 64 years old, following rapid weight loss, abdominal pains, and the development of venous thrombosis.
- At diagnosis, measurable distant lymph node, liver, and lung metastases were observed
- His CA19-9 level was 2760 U/ml and his concentration of albumin was 28 g/L. His ECOG performance status was 1.
Upfront treatment was administered with nab-paclitaxel and gemcitabine, which lasted for 4months:
- At the time of progression, pain levels had increased interfering with daily activity and raising the ECOG performance status to a 2.
- At this point, second-line therapy was initiated with liposomal irinotecan, fluorouracil, and folinic acid.
Advertisement
Related to this article

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
4
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
5












